Home›Stock Screener›Triochem Products

Triochem Products Share Price Today | Stock Price & Triochem Products Share Screener

TRIPR Pharmaceuticals

Track the current Triochem Products share price and stock price live with TickJournal's free stock screener. Check TRIPR 52-week chart for the annual price range and momentum. Use the Triochem Products stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Triochem Products opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹12 and net income of ₹8, with EBITDA of ₹11.

Triochem Products Market Cap ₹0.40 Cr.
TRIPR P/E Ratio (TTM) 15.00
Triochem Products P/B Ratio 0.04
EPS (TTM) ₹325.34
Dividend Yield -
Debt to Equity -
TRIPR 52 Week High -
Triochem Products 52 Week Low -
Operating Margin -
Profit Margin 66.67%
TRIPR Revenue (TTM) ₹12.00
EBITDA ₹11.00
Net Income ₹8.00
Total Assets ₹21.00
Total Equity ₹21.00

Triochem Products Share Price Chart

Track the current stock price of Triochem Products with an interactive chart. Analyse TRIPR share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Triochem Products stock quote in one place.

Triochem Products Company Profile - Fundamental Screener

Screen Triochem Products company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for TRIPR shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE331E01013.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE331E01013

Triochem Products Balance Sheet Screener

Screen TRIPR balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹21, up from ₹14 in 2025.

Latest statistics put total assets at ₹21 and shareholder funds at ₹21.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 21 14 15 12 13 12 17 15 12 10
Current Assets 13 3 3 1 12 11 15 14 10 8
Fixed Assets 0 1 1 1 1 1 1 1 1 2

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 0 0 0 0 0 0 0 0 0 0
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 21 14 15 12 13 12 12 9 8 6
Share Capital 0 0 0 0 0 0 0 0 0 0
Reserves & Surplus 20 13 14 11 13 12 12 9 8 5

Triochem Products Income Statement Screener - Profit & Revenue Analysis

Screen Triochem Products income statement and profit fundamentals. Analyze TRIPR quarterly results. Triochem Products reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹12 and net profit was ₹8, equal to earnings per unit of ₹330.50.

In that period expenses were ₹1, interest cost ₹0 and tax ₹2. The next period listed, 2026-March, shows revenue of ₹1 and net profit of ₹8.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Revenue and Expenses

Revenue 12 1 1 1 0 9 14 21 12 35 18 23 31
Expenses 1 1 1 1 1 8 14 16 11 31 17 22 30

Operating Costs and Margins

EBITDA 11 -1 0 0 -1 2 0 5 2 4 1 1 1
Operating Profit % 0.00% 0.00% 0.00% 0.00% 0.00% 15.00% -3.00% 22.00% 13.00% 11.00% 5.00% 4.00% 4.00%
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 1 0 0 0 0

Profit and Earnings

Profit Before Tax 11 11 0 -1 -1 2 -1 5 1 4 1 1 1
Tax 2 3 0 0 0 0 0 1 0 1 0 0 0
Net Profit 8 8 0 -1 -1 1 0 3 1 3 1 0 0
EPS 330.50 325.34 -16.33 -41.36 -36.12 53.99 -18.24 138.89 30.33 104.29 23.51 13.94 16.98

Triochem Products Cash Flow Screener - Liquidity Fundamentals

Screen TRIPR cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities used ₹3, and net cash flow was an inflow of ₹11.

Over the same period, investing activities provided ₹14 and financing activities provided ₹0.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities -3 0 -4 -1 4 10 4 -4 2 -7
Investing Activities 14 0 3 -10 0 0 0 0 0 4

Financing and Net Cash

Financing Activities 0 0 0 0 0 -3 -4 3 -1 3
Net Cash Flow 11 0 0 -11 4 8 0 -1 1 0

Triochem Products Shareholding Pattern Screener

See Triochem Products shareholding pattern with promoter, FII, and DII holdings. Check Triochem Products promoter holding and ownership changes for TRIPR on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 68.65%, foreign institutions 0.00%, domestic institutions 0.00% and the public 15.53%, spread across 54 shareholders.

The shareholder count was 54 in 2026-Mar, compared with 55 in 2026-Jun.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun

Promoter Holding

Promoter Holding 68.65% 68.65% 68.65% 68.65% 68.65% 68.65% 68.65% 68.65%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 15.53% 15.53% 15.53% 15.53% 15.53% 15.53% 15.53% 15.53%
Other Holding 15.82% 15.82% 15.82% 15.82% 15.82% 15.82% 15.82% 15.82%
Shareholder Count 54 55 55 55 55 54 55 55

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Triochem Products. Triochem Products dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Triochem Products.

Triochem Products Stock Index Membership - Nifty & Sensex

See which indices include Triochem Products stock. Check TRIPR index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Triochem Products is not part of any tracked indices.
Only major market indices are tracked in our system.

Triochem Products Market Events Screener - Corporate Actions

Get Triochem Products corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Triochem Products stock events that may affect TRIPR share price, along with derivatives, futures and options activity and sector gainers.

11 corporate actions are listed, the most recent entry being Annual General Meeting dated August 22, 2026, with a record date of August 22, 2026.

It is followed by Quarterly Result Announcement dated August 14, 2026 and Quarterly Result Announcement dated May 29, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-08-22 2026-08-22 Annual General Meeting NA -
2026-08-14 2026-08-14 Quarterly Result Announcement NA -
2026-05-29 2026-05-29 Quarterly Result Announcement NA -
2026-02-13 2026-02-13 Quarterly Result Announcement NA -
2025-11-12 2025-11-12 Quarterly Result Announcement NA -
2025-08-14 2025-08-14 Quarterly Result Announcement NA -
2025-06-25 2025-06-25 Annual General Meeting NA -
2025-05-24 2025-05-24 Quarterly Result Announcement NA -
2025-02-12 2025-02-12 Quarterly Result Announcement NA -
2024-11-13 2024-11-13 Quarterly Result Announcement NA -
2024-08-22 2024-08-22 Annual General Meeting NA -

Triochem Products Competitors Screener - Peer Stocks Comparison

Screen TRIPR competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 432,120 36.04 61,674 12.69% 11,565 36.68
Divis Laboratories 245,532 84.24 11,067 13.95% 2,568 51.70
Torrent Pharmaceuticals 181,333 84.71 13,886 20.34% 2,138 41.12
Zydus Life Science 114,284 25.27 27,658 17.64% 5,026 47.64
Cipla 108,576 32.50 29,045 2.24% 3,870 34.78
Laurus Labs 107,198 98.20 6,868 22.01% 890 58.70
Mankind Pharma 104,707 50.04 14,636 14.85% 1,938 61.75
Dr Reddys Laboratories 100,679 32.41 35,059 3.90% 4,158 53.84
Aurobindo Pharma 96,479 25.84 34,145 5.56% 3,503 50.30
Lupin 92,885 16.82 29,039 26.75% 5,356 31.59

Triochem Products Company Announcements - News & Reports Screener

Screen TRIPR latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 1, 2026.

The next most recent announcements are dated August 24, 2026 and August 24, 2026.

Date Update Actions
2026-10-01 Closure of Trading Window -
2026-08-24 Announcement under Regulation 30 (LODR)-Meeting Updates -
2026-08-24 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-08-22 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-08-19 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-14 Non-Applicability Of Statement Of Deviation Or Variation Under Regulation 32(1) Of The SEBI (Listing Obligation & Disclosures Requirement) Regulation 2015 For The Quarter Ended 30Th June 2026. -
2026-08-14 Submission Of Unaudited Standalone Financial Results For The Quarter Ended 30Th June 2026 -
2026-08-14 Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday 14Th August 2026 -
2026-08-10 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-08 Board Meeting Intimation for Intimation Of Board Meeting For The Quarter Ended 30Th June 2026 Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-07-31 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-07-30 Reg. 34 (1) Annual Report. -
2026-07-30 Notice Of Fifty-Four Annual General Meeting (AGM) Of The Company Will Be Held On Saturday 22Nd August 2026 -
2026-07-15 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-07-15 Disclosures By Listed Entities Of Defaults On Payment Of Interest/ Repayment Of Principal Amount For Loans Including Revolving Facilities Like Cash Credit From Banks / Financial Institutions -
2026-07-15 Quarterly Disclosures By Listed Entities Of Defaults On Payment Of Interest/ Repayment Of Principal Amount On Loans From Banks / Financial Institutions And Unlisted Debt Securities -
2026-07-15 Compliance-57 (5) : intimation after the end of quarter -
2026-06-30 Compliance-57 (4) : Prior intimation to the beginning of the quarter -
2026-06-30 Closure of Trading Window -
2026-06-01 Announcement under Regulation 30 (LODR)-Newspaper Publication -

Frequently Asked Questions

How is the company valued right now?

The P/E ratio is 15.00 and the P/B ratio is 0.04, with earnings per unit of ₹325.34. Market capitalisation stands at ₹0.40 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Key statistics were last updated on October 5, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.